India Pharma Outlook Team | Thursday, 16 July 2026
The India-UK FTA has sparked a fresh debate across India's pharmaceutical sector. Drugmakers see the agreement as a major export opportunity.
Patient groups, however, fear some intellectual property provisions could affect affordable medicines in the future. The trade deal promises better access to the UK market.
At the same time, it has raised questions about India's ability to protect public health during emergencies.
The trade agreement removes import duties on pharmaceutical products exported from India to the UK. This gives Indian companies better access to one of Europe's biggest healthcare markets. Industry experts believe the move will improve exports of generic drugs and medical devices. They also expect more partnerships in manufacturing and research.
The pharmaceutical industry has largely welcomed the agreement. Companies believe duty-free access will improve their competitiveness in the UK market.
Key benefits include:
The UK is India's largest pharmaceutical export destination in Europe. Yet, India's share in the UK market remains limited. Industry leaders believe the FTA can help Indian companies expand their presence.
Drugmakers also expect the agreement to improve business confidence. Better trade conditions could encourage long-term investments and collaborations between Indian and British firms.
Also Read: Why the Latest Ebola Outbreak Has Global Health Experts on Alert
While the industry celebrates, patient organizations have raised serious concerns. Their focus is on the agreement's voluntary licensing provisions.
They argue the FTA appears to favor voluntary licensing over compulsory licensing. Under voluntary licensing, patent owners decide who can manufacture a medicine. They also decide the commercial terms.
Compulsory licensing allows governments to authorize production without the patent owner's consent. This option is available under specific legal conditions, including public health emergencies.
Patient groups believe limiting compulsory licensing could reduce India's ability to ensure affordable medicines during future health crises. They have urged the government to protect existing legal safeguards.
The Indian government has defended the agreement. Officials say the FTA does not require patent term extensions. It also does not introduce data exclusivity provisions.
The government has clarified that India's patent laws remain unchanged. Officials also said protections like Section 3(d) continue to remain in force. These safeguards have played a major role in supporting the country's generic drug industry.
According to the government, the agreement balances trade growth with public health interests. Officials maintain that India has not accepted any obligation that would weaken its existing patent framework.
The India-UK FTA has opened new opportunities for pharmaceutical exports. At the same time, it has sparked fresh debate over intellectual property and access to medicines. The industry sees stronger business prospects. Patient groups want stronger assurances that public health protections will remain intact. How the agreement is implemented will determine whether both goals can be achieved.
